Home » Stocks » Cocrystal Pharma

Cocrystal Pharma, Inc. (COCP)

Stock Price: $1.66 USD -0.02 (-0.90%)
Updated Jul 14, 2020 12:06 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 86.29M
Revenue (ttm) 1.95M
Net Income (ttm) -53.13M
Shares Out 52.14M
EPS (ttm) -1.54
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 14, 2020
Last Price $1.66
Previous Close $1.67
Change ($) -0.02
Change (%) -0.90%
Day's Open 1.65
Day's Range 1.55 - 1.66
Day's Volume 1,344,453
52-Week Range 0.39 - 2.95

More Stats

Market Cap 86.29M
Enterprise Value 65.23M
Earnings Date (est) Aug 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 52.14M
Float 30.70M
EPS (basic) -1.66
EPS (diluted) -1.54
FCF / Share -0.14
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 156,231
Short Ratio 0.03
Short % of Float 0.42%
Beta 0.04
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 44.32
PB Ratio 2.31
Revenue 1.95M
Operating Income -53.24M
Net Income -53.13M
Free Cash Flow -5.98M
Net Cash 21.06M
Net Cash / Share 0.40
Gross Margin 131.48%
Operating Margin -2,734.67%
Profit Margin -2,728.80%
FCF Margin -307.24%
ROA -7.49%
ROE -93.01%
ROIC -6,136.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$5.00*
(202.11% upside)
Low
5.00
Current: 1.66
High
5.00
Target: 5.00
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue6.56---0.080.01--12.6115.25
Revenue Growth----766.67%----17.36%-
Gross Profit6.56---0.080.01--2.696.83
Operating Income-48.41-62.92-8.26-106-53.95-5.80-4.08-2.55-3.89-0.03
Net Income-48.17-49.05-0.61-74.87-50.12-0.10-3.89-7.96-5.46-0.32
Shares Outstanding31.8628.0124.1323.5221.0110.891.912.051.681.49
Earnings Per Share-1.51-1.75-0.03-3.30-2.40-0.30-2.10-3.90-3.30-0.30
Operating Cash Flow-1.56-8.29-6.90-14.66-10.32-6.01-3.69-1.59-0.42-0.26
Capital Expenditures-0.15-0.03-0.04-0.05-0.34-0.01--0.15-0.58-0.36
Free Cash Flow-1.71-8.32-6.94-14.71-10.66-6.02-3.69-1.74-1.00-0.62
Cash & Equivalents7.522.792.104.979.486.141.050.010.420.25
Total Debt0.820.331.01----2.397.336.93
Net Cash / Debt6.702.461.104.979.486.141.05-2.38-6.92-6.68
Assets28.5368.561211252242591.667.247.557.53
Liabilities2.821.6716.0322.5656.6474.410.3910.8210.328.12
Book Value25.7166.891051021686.65-8.83-3.58-2.77-0.59
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Cocrystal Pharma, Inc.
Country United States
Employees 11
CEO Gary L. Wilcox

Stock Information

Ticker Symbol COCP
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: COCP

Description

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that is in Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.